Jody Lawrence
About
Jody Lawrence is a scholar working on Infectious Diseases, Virology and Epidemiology.
According to data from OpenAlex, Jody Lawrence has authored 34 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 29 papers in Infectious Diseases, 15 papers in Virology and 11 papers in Epidemiology. Recurrent topics in Jody Lawrence's work include HIV Research and Treatment (15 papers), HIV/AIDS drug development and treatment (13 papers) and Viral gastroenteritis research and epidemiology (10 papers). Jody Lawrence is often cited by papers focused on HIV Research and Treatment (15 papers), HIV/AIDS drug development and treatment (13 papers) and Viral gastroenteritis research and epidemiology (10 papers). Jody Lawrence collaborates with scholars based in United States, United Kingdom and Finland. Jody Lawrence's co-authors include Mark A. Winters, Jonathan Schapiro, Thomas C. Merigan, Clive M. Gray, John D. Altman, John D. Baxter, Smriti K. Kundu, Katherine Huppler Hullsiek, Mark M. Davis and Donald I. Abrams and has published in prestigious journals such as New England Journal of Medicine, The Journal of Immunology and PLoS ONE.
In The Last Decade
Jody Lawrence
31 papers receiving 1.1k citations
Peers
Jody Lawrence
Maria Franca Pirillo Italy
Sirirat Likanonsakul Thailand
Gugu Maphalala United States
Scott Hammer United States
Jorge Villacian Singapore
Madhu Vajpayee India
David Dalmau Spain
Christopher F. Rowley United States
Roberto Novati Italy
José Antonio Iribarren Spain
Citations per year, relative to Jody Lawrence Jody Lawrence (= 1×)
peers
Maria Franca Pirillo
Countries citing papers authored by Jody Lawrence
Since
Specialization
Citations
This map shows the geographic impact of Jody Lawrence's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jody Lawrence with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jody Lawrence more than expected).
Fields of papers citing papers by Jody Lawrence
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Jody Lawrence. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jody Lawrence. The network helps show where Jody Lawrence may publish in the future.
Co-authorship network of co-authors of Jody Lawrence
This figure shows the co-authorship network connecting the top 25 collaborators of Jody Lawrence. A scholar is included among the top collaborators of Jody Lawrence based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jody Lawrence. Jody Lawrence is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
McCrea, G. Lindsay, Sean Daly, Charlie Zhang, et al.. (2025). The synergistic interplay between vitamin A, dietary fiber, and the microbiota-gut-brain axis: a potential mechanism for preventing Alzheimer’s disease. American Journal of Physiology-Gastrointestinal and Liver Physiology. 329(3). G484–G499.
2.
Lawrence, Jody, Nicholas Kitchin, Annaliesa S. Anderson, et al.. (2021). Safety and immunogenicity of different Clostridioides (Clostridium) difficile vaccine formulations in two early phase randomized studies of healthy adults aged 50–85 years. Vaccine. 39(40). 5991–6003.
3.
Stevens, Vanessa, Yinong Young‐Xu, Molly Leecaster, et al.. (2020). Identification of patients at risk of Clostridioides difficile infection for enrollment in vaccine clinical trials. Vaccine. 39(3). 536–544.
4.
Heylen, Elisabeth, Mark Zeller, Max Ciarlet, et al.. (2016). Human P[6] Rotaviruses From Sub-Saharan Africa and Southeast Asia Are Closely Related to Those of Human P[4] and P[8] Rotaviruses Circulating Worldwide. The Journal of Infectious Diseases. 214(7). 1039–1049.
5.
Heylen, Elisabeth, Mark Zeller, Max Ciarlet, et al.. (2015). Comparative analysis of pentavalent rotavirus vaccine strains and G8 rotaviruses identified during vaccine trial in Africa. Scientific Reports. 5(1). 14658–14658.
6.
Iwata, Satoshi, Shuji Nakata, Susumu Ukae, et al.. (2013). Efficacy and safety of pentavalent rotavirus vaccine in Japan. Human Vaccines & Immunotherapeutics. 9(8). 1626–1633.
7.
Lawrence, Jody, Shuangba He, Darcy A. Hille, et al.. (2012). A study of RotaTeq™ (pentavalent rotavirus vaccine) in Chinese healthy adults, children and infants. International Journal of Infectious Diseases. 16. e307–e307.
8.
Paquet, Agnès, John D. Baxter, Jodi Weidler, et al.. (2011). Differences in Reversion of Resistance Mutations to Wild-Type under Structured Treatment Interruption and Related Increase in Replication Capacity. PLoS ONE. 6(1). e14638–e14638.
9.
German, Polina, Sunil Parikh, Jody Lawrence, et al.. (2009). Lopinavir/Ritonavir Affects Pharmacokinetic Exposure of Artemether/Lumefantrine in HIV-Uninfected Healthy Volunteers. JAIDS Journal of Acquired Immune Deficiency Syndromes. 51(4). 424–429.
10.
Vesikari, Timo, et al.. (2008). Efficacy of Pentavalent Rotavirus Vaccine, RotaTeq™, against Hospitalizations and Emergency Department Visits through the Third Year: The Finnish Extension Study. International Journal of Infectious Diseases. 12. e149–e149.
11.
Mannheimer, Sharon, Lisa Thackeray, Katherine Huppler Hullsiek, et al.. (2008). A randomized comparison of two instruments for measuring self-reported antiretroviral adherence. AIDS Care. 20(2). 161–169.
12.
Lawrence, Jody, Katherine Huppler Hullsiek, Lisa Thackeray, et al.. (2006). Disadvantages of Structured Treatment Interruption Persist in Patients With Multidrug-Resistant HIV-1. JAIDS Journal of Acquired Immune Deficiency Syndromes. 43(2). 169–178.
13.
Kozal, Michael J., Katherine Huppler Hullsiek, Robert Leduc, et al.. (2006). Prevalence and Impact of HIV-1 Protease Codon 33 Mutations and Polymorphisms in Treatment-Naive and Treatment-Experienced Patients. Antiviral Therapy. 11(4). 457–463.
14.
Kilby, J Michael, R. Pat Bucy, Donna Mildvan, et al.. (2006). A Randomized, Partially Blinded Phase 2 Trial of Antiretroviral Therapy, HIV‐Specific Immunizations, and Interleukin‐2 Cycles to Promote Efficient Control of Viral Replication (ACTG A5024). The Journal of Infectious Diseases. 194(12). 1672–1676.
15.
Lawrence, Jody, Douglas L. Mayers, Katherine Huppler Hullsiek, et al.. (2003). Structured Treatment Interruption in Patients with Multidrug-Resistant Human Immunodeficiency Virus. New England Journal of Medicine. 349(9). 837–846.
16.
Haas, David W., G. Wilkinson, Daniel R. Kuritzkes, et al.. (2003). A Multi-Investigator/Institutional DNA Bank for AIDS-Related Human Genetic Studies: AACTG Protocol A5128. HIV Clinical Trials. 4(5). 287–300.
17.
Gray, Clive M., Jody Lawrence, Erik A. Ranheim, et al.. (2000). Highly Active Antiretroviral Therapy Results in HIV Type 1 Suppression in Lymph Nodes, Increased Pools of Naive T Cells, Decreased Pools of Activated T Cells, and Diminished Frequencies of Peripheral Activated HIV Type 1-Specific CD8 + T Cells. AIDS Research and Human Retroviruses. 16(14). 1357–1369.
18.
Schapiro, Jonathan, Mark A. Winters, Jody Lawrence, & Thomas C. Merigan. (1999). Clinical cross-resistance between the HIV-1 protease inhibitors saquinavir and indinavir and correlations with genotypic mutations. AIDS. 13(3). 359–365.
19.
Lawrence, Jody, Jonathan Schapiro, Mark A. Winters, et al.. (1999). Clinical Resistance Patterns and Responses to Two Sequential Protease Inhibitor Regimens in Saquinavir and Reverse Transcriptase Inhibitor–Experienced Persons. The Journal of Infectious Diseases. 179(6). 1356–1364.
20.
Gray, Clive M., Jody Lawrence, Jonathan Schapiro, et al.. (1999). Frequency of Class I HLA-Restricted Anti-HIV CD8+ T Cells in Individuals Receiving Highly Active Antiretroviral Therapy (HAART). The Journal of Immunology. 162(3). 1780–1788.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Maria Franca Pirillo Breakdown of academic impact, for papers by Sirirat Likanonsakul Breakdown of academic impact, for papers by Gugu Maphalala Breakdown of academic impact, for papers by Scott Hammer Breakdown of academic impact, for papers by Jorge Villacian Breakdown of academic impact, for papers by Madhu Vajpayee Breakdown of academic impact, for papers by David Dalmau Breakdown of academic impact, for papers by Christopher F. Rowley Breakdown of academic impact, for papers by Roberto Novati Breakdown of academic impact, for papers by José Antonio Iribarren